Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis

J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):236-8. doi: 10.1136/jnnp-2014-307786. Epub 2014 Apr 30.

Authors

Luca Prosperini¹, Floriana De Angelis¹, Rosanna De Angelis¹, Fulvia Fanelli¹, Carlo Pozzilli¹

Affiliation

¹ Multiple Sclerosis Centre, S. Andrea Hospital, Rome, Italy Department of Neurology and Psychiatry, Sapienza University, Rome, Italy.

PMID: 24790213
DOI: 10.1136/jnnp-2014-307786

No abstract available

Keywords: MRI; MULTIPLE SCLEROSIS.

Publication types

Letter
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Disability Evaluation*
Female
Follow-Up Studies
Humans
Immunosuppressive Agents / therapeutic use*
Magnetic Resonance Imaging
Male
Multiple Sclerosis / drug therapy*
Multiple Sclerosis / pathology*
Natalizumab
Neuroimaging
Recovery of Function / drug effects*
Recurrence
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Natalizumab